Table 8.

PD-L1 expression in NSCLC according to the patients’ gender and EGFR mutation status

	PD-L1 expression
	TPS < 1% (None)	TPS 1% to 49% (Low)	TPS ≥ 50% (High)	P value
Male (n = 115)
EGFR mutation-positive (n = 31)	10 (32.3%)	18 (58.1%)	3 (9.7%)	0.028*
EGFR mutation-negative (n = 84)	30 (35.7%)	29 (34.5%)	25 (29.8%)
Female (n = 76)
EGFR mutation-positive (n = 50)	23 (46.0%)	24 (48.0%)	3 (6.0%)	0.026*
EGFR mutation-negative (n = 26)	9 (34.6%)	10 (38.5%)	7 (26.9%)

TPS = Tumor proportion score

^*Comparison between high PD-L1 expression (TPS ≥ 50%) versus no (TPS < 1%) and low PD-L1 expression (TPS ≤ 50%) in EGFR-mutant versus EGFR wild-type NSCLC patients